학술논문
The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial).
Document Type
Journal Article
Author
Source
Subject
*HORMONE receptor positive breast cancer
*EPIRUBICIN
*DOCETAXEL
*CANCER chemotherapy
*HORMONE therapy
*CANCER treatment
*THERAPEUTICS
*
*
*
*
*
*
Language
ISSN
1471-2407
Abstract